

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 15 NO 4 DECEMBER 1998

ISSN 0790-9667



An advance in first-line treatment of depression and associated anxiety



DIRECTLY ACTS ON BOTH
SEROTONIN AND NORADRENALINE^{1,2†}



HIGH RESPONSE RATES
IN DEPRESSION^{3,4}



EFFECTIVE RELIEF OF ASSOCIATED
ANXIETY SYMPTOMS³



LOW POTENTIAL FOR DRUG
INTERACTIONS^{**5-8}

† ANIMAL STUDIES
** HEALTHY VOLUNTEER STUDIES

EFEXOR^{*}

VENLAFAXINE 37.5mg b.d.

SEROTONIN NORADRENALINE REUPTAKE INHIBITOR

ABBREVIATED PRESCRIBING INFORMATION EFEXOR^{*}

Venlafaxine Presentation: Tablets containing 37.5mg or 75mg venlafaxine (as hydrochloride) **Use:** Treatment of depressive illness, including depression accompanied by anxiety. **Dosage:** Usually 75mg/day (37.5mg bd) with food, increasing to 150mg/day (75mg bd) if necessary. In more severely depressed patients, 150mg/day (75mg bd) increasing every 2 or 3 days in up to 75mg/day increments to a maximum of 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually to reduce the possibility of withdrawal reactions. **Elderly:** use normal adult dose with caution. **Children:** contra-indicated. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. **Contra-indications:** Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. **Precautions:** Use with caution in patients with myocardial infarction, unstable heart disease, renal or hepatic impairment, or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their ability to do so is impaired. Possibility of postural hypotension (especially in

the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets to reduce the risk of overdose. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should a rash or an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. **Interactions:** MAOIs: do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting an MAOI. **Side-effects:** Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety, impotence, abnormality of accommodation, vasodilation, vomiting, tremor, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise in blood pressure, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol, hyponatraemia. Symptoms reported on

discontinuation of venlafaxine were mostly non-serious and self-limiting and included dizziness, insomnia, nausea and nervousness. **Product Authorisation Numbers:** 37.5mg tablet: PA 22/65/2; 75mg tablet: PA 22/65/4. **Legal category:** S1A. For full prescribing information please refer to the Summary of Product Characteristics. **Product Authorisation Holder:** Wyeth Laboratories, Taplow, Maidenhead, Berkshire, SL6 0PH, UK. Further information may be obtained from: Wyeth Laboratories, 765 South Circular Road, Islandbridge, Dublin 8. * trade mark. **References:** 1. Muth EA *et al.* *Biochem Pharmacol* 1986; 35(24): 4493-4497. (EX00007). 2. Muth EA *et al.* *Drug Development Research* 1991; 23: 191-199. (EX00022). 3. Dierick M *et al.* *Prog Neuropsychopharmacol Biol Psychiatry* 1996; 20: 57-71. 4. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9(3): 139-143. (EX00101). 5. Troy SM *et al.* *J Clin Pharmacol* 1996; 36: 175-181 (106814). 6. Troy SM *et al.* *J Clin Pharmacol* 1995; 35: 410-419. 7. Troy SM *et al.* *J Clin Pharmacol* 1998; 38: 467-474 (120224). 8. Amchin J. *Clin Pharmacol and Ther* 1997; 61 (2): 179. **Wyeth** Code: Z779180/0998. Date of preparation: September 1998.

Editor-in-Chief: Brian Lawlor

Editorial Co-ordinator:

Niamh Gleeson

Editorial Assistant: Anne Henriksen

Advertising Manager:

Mary Kate O'Flanagan

Founding Editor: Mark Hartman

Editors: Timothy Dinan (London),
David King (Belfast)

Deputy Editor: Brian O'Shea (Dublin)

Associate Editors: Ken Brown (Belfast), Patricia Casey (Dublin), Anthony Clare (Dublin), Stephen Cooper (Belfast), Thomas Fahy (Galway), Michael Fitzgerald (Dublin), Michael Kelleher (Cork), Brian Leonard (Galway), Roy McClelland (Belfast), Aidan McGennis (Dublin), Ciaran O'Boyle (Dublin), Eadbhard O'Callaghan (Dublin), Art O'Connor (Dublin), Ethna O'Gorman (Belfast), Ian Pullen (Edinburgh), David Sheehan (Tampa), Philip Snaith (Leeds), Hugh Staunton (Dublin), John Waddington (Dublin), Richard Williams (Calgary)

Statistical Editor: Leslie Daly (Dublin)

Deputy Statistical Editor:

Ronan Conroy (Dublin)

Submissions & correspondence to:

The Editor,
Irish Journal of Psychological Medicine,
99 Upper George's Street,
Dun Laoghaire, Co Dublin.

Telephone

01-2803967; Int: +353-1-2803967

Fax

01-2807076; Int: +353-1-2807076

Publisher

MedMedia Ltd.
Media House,
99 Upper George's Street,
Dun Laoghaire, Co Dublin.

Printing: New Cityview Press

Subscriptions

Rates per volume of four issues
(Mar, Jun, Sept, Dec)
STG£43 EU, US\$96 USA, STG£53
elsewhere (single issues US\$28 USA,
STG£13.25 elsewhere) incl. airmail
postage internationally.

**Subscription enquiries, orders
and cheques made payable to:**

Royal Society of Medicine Press Ltd.,
1 Wimpole St, London, W1M 8AE, UK.

Tel: 0171-2902927;
int: +44-171-2902927.
Fax: 0171-2902929;
int: +44-171-2902929.

Circulation

3,000 to 54 countries.
Journal participates in the World Health
Organisation project to improve
distribution of scientific materials on
mental health.
Publication does not imply
endorsement. Limited photocopying
authorisation granted for a fee to
Copyright Clearance Center,
27 Congress Street, Salem, MA 01970,
USA, or to appropriate Reproduction
Rights Organisation; isolated non-profit,
academic photocopying excepted.

EDITORIAL

117 Consent to treatment and people with learning disabilities

John Hillery, David Tomkin, Adam McAuley, Verena Keane & Mary Staines

ORIGINAL PAPERS

119 Contemporary psychosurgery: indications, outcome and the Irish experience

Miriam O'Doherty & Paul K Bridges

123 Sexual abuse in childhood and subsequent illicit drug abuse in adolescence and early adulthood

Roy Browne, Shay Keating & John O'Connor

127 An economic evaluation of inpatient treatment versus day hospital care for psychiatric patients

Eamon O'Shea, Jenny Hughes, Lourde Fitzpatrick, Elizabeth Dunne, Mary O'Sullivan & Margaret Cole

BRIEF REPORTS

131 Dyads and triads of abuse, bereavement and separation: a survey in children attending a child and family centre

Declan Sheerin

135 A study of sex offending in elderly people referred to a specialised psychiatry of old age service

Angela McAleer & Margo Wrigley

139 Mental illness in an elderly rural population in Ireland: a prevalence study

Margaret Kelleher, Mary O'Sullivan & Nuala McMahon

AUDIT

142 Audit of the first year of a psychiatric clinic at a Dublin Maternity Hospital

Miriam Gannon, Siobhan Barry & Michael Turner

APPRECIATION

145 Dr Michael Kelleher

Marcus Webb

144a John Dunne Medal

146 Index to Keywords 1998

148 Index to Authors 1998

150 Guidelines for authors

Cover illustration: 'The Blind Piper', Joseph Haverly (1794-1864)


Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST; PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from **University Microfilms International**, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the **Adonis** service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from **ADONIS BV**, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in **Ulrich's International Periodicals Directory** (**Bowker** International Serials Database), **EBSCO's** Selected Periodicals for the Medical and Health Sciences, & **EBSCO's** Librarians' Handbook.



Fast Response

Can start to improve symptoms within seven days



FIRST CHOICE
LUSTRAL™ 50mg
 sertraline

A first choice antidepressant



Abbreviated Prescribing Information:
LUSTRAL™ (sertraline)

Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. Obsessive compulsive disorder (OCD). **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual antidepressant dose is 50mg. Dosage can be further increased, if appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose. **Use in children:** Not recommended. **Use in elderly:** Usual adult dose. **Contra-indications:** Hypersensitivity to this group of drugs. Hepatic insufficiency, unstable epilepsy and convulsant disorders, pregnancy and lactation.

MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Precautions, warnings:** Renal insufficiency, ECT, epilepsy, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered with benzodiazepines or other tranquilizers in patients who drive or operate machinery. The patient should be monitored for signs of suicide or mania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs such as tryptophan or fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for Lustral to interact with other highly protein bound drugs should be borne in mind. Interactions with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor,

increased sweating, dizziness, insomnia, somnolence, headache and dyspepsia. Rarely, abnormal LFTs, hyponatraemia. The following have been reported with Lustral but may have no causal relationship: movement disorders, convulsions, menstrual irregularities, hyperprolactinaemia, galactorrhoea and rash. As with other serotonin re-uptake inhibitors rare reports of agitation, confusion, depersonalisation, hallucinations, nervousness, postural hypotension, hypo/hypertension, tachycardia and arrhythmias. As with all psychoactive medicines, possible side effects on discontinuation, such as dizziness, sensory disturbance, sleep disturbance, agitation or anxiety, nausea and sweating. **Legal Category:** S1A. **Package Quantities:** 50mg tablet (PA 822/1/4) Calendar pack of 28; 100mg tablet (PA 822/1/5) Calendar pack of 28. **Product Authorisation Holder:** Pfizer (Ireland) Limited, Pharmapark, Chapelizod, Dublin 20, Republic of Ireland. **Further information on request:** Pfizer (Ireland) Limited. Date last revised: 1/11/96 66973 June 97

